The health care provider recommends daily fiber supplements for an elderly client who is experiencing frequent constipation. What statement is important for the nurse to include when educating a client about these supplements?

Choice A reason: Bulk-forming fiber supplements, like psyllium, increase stool bulk without significantly decreasing nutrient absorption. While high doses may slightly affect mineral uptake, routine vitamin supplementation is not required. This statement is inaccurate, as nutrient malabsorption is not a primary concern with fiber supplements.

Choice B reason: Fiber supplements require adequate hydration (at least 8 glasses of water daily) to swell and soften stool, promoting bowel movements. Insufficient water can cause fiber to harden, worsening constipation. This statement is accurate, as hydration is critical for the efficacy and safety of fiber supplements.

Choice C reason: Long-term fiber use does not cause dependency; it mimics natural dietary fiber, promoting regular bowel movements. The colon adapts to increased bulk without losing intrinsic motility. This statement is inaccurate, as fiber supports, not undermines, normal bowel function in chronic use.

Choice D reason: Delaying the urge to defecate can worsen constipation by causing stool to harden and reducing rectal sensitivity. Prompt response to bowel urges promotes regularity. This statement is inaccurate, as it contradicts the goal of improving bowel regimen with fiber supplementation.

Choice A reason: Cognitive enhancers like donepezil or memantine are prescribed based on Alzheimer’s disease stage. Cholinesterase inhibitors are effective in mild-to-moderate stages, enhancing acetylcholine levels to improve cognition. Memantine, an NMDA receptor antagonist, is used in moderate-to-severe stages to regulate glutamate activity, slowing cognitive decline. This statement is accurate, as treatment is tailored to symptom severity.

Choice B reason: Cognitive enhancers are not equally effective in all Alzheimer’s stages. Cholinesterase inhibitors benefit mild-to-moderate cases, while memantine is used in severe stages. Their efficacy diminishes in advanced disease due to extensive neuronal loss, making this statement inaccurate, as stage-specific prescribing is critical for therapeutic benefit.

Choice C reason: Medications for anxiety and depression, like SSRIs, remain helpful in Alzheimer’s to manage behavioral symptoms, even with cognitive enhancers. These drugs address mood disorders, which often coexist, improving quality of life. This statement is inaccurate, as combination therapy is common and beneficial in managing neuropsychiatric symptoms.

Choice D reason: Cognitive enhancers are not used for seizure management. Anticonvulsants like levetiracetam manage seizures, which may occur in Alzheimer’s due to neuronal excitability. Cognitive enhancers target cognitive decline via cholinergic or glutamatergic pathways, not seizure control, making this statement inaccurate and unrelated to their pharmacological role.